Phase 3
Completed N=54
Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature
Growth Disorder · idiopathic short stature
Source: ClinicalTrials.gov NCT01778023 ↗
Enrolled (actual)
54
Serious AEs
11.8%
Results posted
Oct 2016
Primary outcomePrimary: Height Velocity (Ht-V) — 12.02; 6.87 cm/year — p=<0.0001
◆ Published Evidence
Emerging
5citations · ~1 / year
Efficacy and Safety Evaluation of Human Growth Hormone Therapy in Patients with Idiopathic Short Stature in Korea - A Randomised Controlled Trial.
Summary
This trial is conducted in Asia. The aim of this trial is to evaluate the efficacy and safety of recombinant human growth hormone (hGH) in subjects with idiopathic short stature in Korea.
Linked Publications
-
Efficacy and Safety Evaluation of Human Growth Hormone Therapy in Patients with Idiopathic Short Stature in Korea - A Randomised Controlled Trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Height Velocity (Ht-V) |
12.02; 6.87 | <0.0001 sig |
| SECONDARY Change in Ht-SDS (Height Standard Deviation Score) |
0.76; 0.19 | — |
| SECONDARY Change in IGF Related Factors: IGF-I (Insulin-like Growth Factor-I) |
192.58; 28.03 | — |
| SECONDARY Change in IGF Related Factors: IGFBP-3 (Insulin-like Growth Factor Binding Protein-3) |
0.89; 0.22 | — |
| SECONDARY Change in Bone Age |
0.5; 0.5 | — |
| SECONDARY Occurrence of Adverse Events |
70; 25 | — |
| SECONDARY Ht-V (Height Velocity) |
2.80 | — |
Eligibility Criteria
Inclusion Criteria
- Informed consent obtained from subject's parents or legally acceptable representative before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject.)
- Pre-pubertal status (males aged from 4 to 11 [both inclusive], females aged from 4 to 9 [both inclusive]): an absence of breast development in females (Tanner 1 only) and testicular volume below 4 mL in males
- Growth hormone level above 10 ng/mL following a stimulation test (test result within 6 months from screening can be used)
- Height below 3 percentile
- Bone age below or equal to 12 year
- Epiphyses confirmed as open in patients at least 10 years or more of age
Exclusion Criteria
- Known presence of one or more pituitary hormone deficiencies (ACTH (adrenocorticotropic hormone), ADH (antidiuretic hormone), FSH (follicle-stimulating hormone), LH (luteinising hormone), TSH (thyroid-stimulating hormone))
- Known primary hypothyroidism, adrenal insufficiency or hypogonadism (treated or untreated)
- Specific types of growth failure including, but not limited to, known chromosomal abnormalities associated with growth failure and altered sensitivity to growth hormone
- Bone age is advanced over chronological age more than 3 years
- Active malignancy, CNS (central nervous system) trauma, active chemotherapy or radiation therapy for neoplasia
- Prior history of intracranial hypertension
- Hypertrophic cardiomyopathy
Data sourced from ClinicalTrials.gov (NCT01778023) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.